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ABSTRACT
Objective To undertake a cost effectiveness analysis
comparing first and second generation endometrial
ablative techniques, hysterectomy, and the
levonorgestrel releasing intrauterine system (Mirena) for
treating heavy menstrual bleeding.
DesignModel based economic evaluation with data from
an individual patient data meta-analysis supplemented
with cost and outcome data from published sources
taking an NHS (National Health Service) perspective. A
state transition (Markov) model was developed, the
structure being informed by the reviews of the trials and
clinical input. A subgroup analysis, one way sensitivity
analysis, and probabilistic sensitivity analysis were also
carried out.
Population Four hypothetical cohorts of women with
heavy menstrual bleeding.
Interventions One of four alternative strategies: Mirena,
first or second generation endometrial ablation
techniques, or hysterectomy.
Main outcome measures Cost effectiveness based on
incremental cost per quality adjusted life year (QALY).
Results Hysterectomy is the preferred strategy for the first
intervention for heavy menstrual bleeding. Although
hysterectomy is more expensive, it produces more QALYs
relative to other remaining strategies and is likely to be
considered cost effective. The incremental cost
effectiveness ratio for hysterectomy compared with
Mirena is £1440 (€1633, $2350) per additional QALY. The
incremental cost effectiveness ratio for hysterectomy
compared with second generation ablation is £970 per
additional QALY.
Conclusion In light of the acceptable thresholds used by
the National Institute for Health and Clinical Excellence,
hysterectomy would be considered the preferred strategy
for the treatment of heavymenstrual bleeding. The results
concur with those of other studies but are highly sensitive
to utility values used in the analysis.
INTRODUCTION
Heavy menstrual bleeding is a common problem1 that
affects about 1.5 million women in England and
Wales.2 The condition prompts one in 20 women of
reproductive age to consult her general practitioner
and accounts for 20% of all referrals to gynaecology
outpatients.2 Heavymenstrual bleeding can cause con-
siderable distress to women by affecting their perfor-
mance at work as well as social activities and leads to a
measurable reduction in quality of life.3 Traditionally,
the definitive treatment was surgery: in the past, by the
age of 55 one in five women in the United Kingdom
had had a hysterectomy,4 over half of which were for
heavy menstrual bleeding.5
First line treatments for heavy menstrual bleeding
include oral drug regimens such as tranexamic acid,
mefenamic acid, and the combined contraceptive pill.
More recently an alternative medical option is avail-
able in the levonorgestrel intrauterine system (Mir-
ena). This intrauterine contraceptive device works to
reduce menstrual loss by local release of progestogen
and can be fitted in primary or secondary care.6 Surgi-
cal treatments include first and second generation
endometrial ablation, which destroys the lining of the
cavity of the uterus (endometrium).6 First generation
techniques typically required direct hysteroscopic
vision and include endometrial laser ablation, transcer-
vical resectionof the endometrium, and rollerball abla-
tion. Second generation techniques are typically non-
hysteroscopic, vision control is not required, and they
tend to be easier to perform. These latter techniques
include fluid filled thermal balloon endometrial abla-
tion, radiofrequency (thermoregulated) balloon endo-
metrial ablation, and microwave endometrial ablation
(MEA). Hysterectomy, surgical removal of the uterus,
was the only surgical solution until the advent of abla-
tion techniques and is still used when other treatments
fail.6
Between 2000 and 2005 the number of hysterec-
tomies performed for heavy menstrual bleeding fell
from over 20 000 to just over 7000. Instead, 9701
women underwent endometrial ablation; over half of
these (5457) were performed by means of second gen-
eration (non-hysteroscopic) techniques.6 7 The use of
Mirena has increased concurrently, though its
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widespread use for contraception across many clinical
settings in primary and secondary care means that it is
difficult to gather accurate data on numbers prescribed
for heavymenstrual bleeding. Though some follow-up
studies have concentrated on short and medium term
outcomes after hysterectomy and endometrial abla-
tion, there have been few long termcontrolled compar-
isons of hysterectomy with ablation techniques in
women with heavy menstrual bleeding.7
As part of a widerNIHRHealth TechnologyAssess-
ment project tasked to assess the existing evidence on
effectiveness through ameta-analysis of non-oral treat-
ments for heavymenstrual bleeding using data on indi-
vidual patients,6 we carried out an economic
evaluation to determine the relative cost effectiveness
of the four alternative non-oral interventions—hyster-
ectomy, first and second generation endometrial abla-
tion, and Mirena—for the treatment of heavy
menstrual bleeding. Although it is a non-surgical inter-
vention, we included Mirena in the analysis for com-
parison primarily because it is the intervention that the
National Institute for Health and Clinical (NICE)
favours for this condition.8
METHODS
We have already published a systematic review and
individual patient data meta-analysis of available
evidence.7 Briefly, we used individual patient data as
far as possible, supplemented with the trial data as
necessary. Individual patient data on 2814 women
were available from 17 of the 30 randomised con-
trolled trials identified (14 trials (2448 women) for
first versus second generation endometrial ablation;
seven trials (1127 women) for hysterectomy versus
first generation endometrial ablation; five trials (304
women) for second generation endometrial ablation
versus Mirena; three trials (190 women) for first gen-
eration endometrial ablation versus Mirena; one trial
(236 women) for hysterectomy versus Mirena). Direct
and indirect comparisons were made when appropri-
ate to assess the effect of interventions on the primary
outcome measure of patient’s dissatisfaction.
Given the reliance on secondary data and the nature
of available data, the model based economic evalua-
tion takes the form of a cost utility analysis and was
carried out from a UK National Health Service
(NHS) perspective in a secondary care setting.
Cost effectiveness model
Themodelwas developed through consultationwithin
the research team, drawing on the requisite clinical and
modelling expertise. We developed a new state transi-
tion (Markov) model in Microsoft Excel, using as a
starting point an existing model developed by Garside
et al.9 In running the model we compared the progress
of a hypothetical cohort of women with heavy men-
strual bleeding when they are treated by four alterna-
tive interventions: Mirena, first generation
endometrial ablation techniques, second generation
endometrial ablation techniques, and hysterectomy.
We compared the four alternative interventions in
four alternative treatment strategies. The pathway of
the strategy is defined by the intervention that is tried
first. For example, the second generation endometrial
ablation strategy is so called because that is the inter-
vention first in the pathway; if it works for any particu-
lar woman, her treatment will stop there.However, the
pathways are constructed to follow logical clinical evi-
dence basedprogression. Each progression in the path-
way reflects the next likely option, assuming that the
patient returns seeking further treatment because she is
dissatisfied with the outcome from the previous treat-
ment. So, for instance, the strategy referred to as sec-
ond generation ablation might also include a repeat
ablation and even a hysterectomy later in the strategy.
We include a strategy to represent first generation
Menorrhagia
Mirena
Second
generation
techniques
Hysterectomy Well Repeat
ablation (first
generation)
Repeat
ablation (first
generation)
Hysterectomy Well Hysterectomy Well Well
Well Well
First generation endometrial
ablation techniques
Second generation endometrial
ablation techniques
Hysterectomy
Repeat
ablation (first
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Hysterectomy Well Hysterectomy Well Hysterectomy Well
Hysterectomy Well
Well
Fig 1 | Clinical pathways within model for determination of cost effectiveness of different treatments for heavy menstrual bleeding. Names of strategies denote
first intervention undertaken
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endometrial ablation and a separate strategy to repre-
sent second generation endometrial ablation.
Although first generation ablation might sound like
an approach that has been superseded by second gen-
eration ablative techniques, outcomes from first gen-
eration techniques are still acceptable, and the
technique is sometimes considered more versatile
than some second generation approaches. For exam-
ple, they are used if visualising the cavity at time of
treatment is deemed important. Furthermore, first gen-
eration ablative techniques must be the technique of
choice when repeat treatments are required, whether
or not the preceding treatment was first or second gen-
eration ablation. Neither of the ablative techniques
preserves fertility. The only intervention that preserves
fertility isMirena. The hysterectomy strategy is offered
to a woman for whom the only acceptable outcome is
amenorrhoea. In the hysterectomy strategy, all other
steps are bypassed and hysterectomy is the only inter-
vention.
Figure 1 shows the clinical pathways on which the
model is based. Health states are shown in boxes, and
arrows show the transitions that can occur. The health
states and pathways are the same for both types of
endometrial ablation techniques. Table 1 presents a
summary of the health states for each pathway.
In this model, the hypothetical cohort of patients
moves between discrete health states to replicate the
natural course of the condition, with each state having
associated costs and quality of life. In such a model,
transition probabilities, costs, and quality of life differ
according to the use of the alternative techniques used
to treat the clinical problem.Thedifference in outcome
and costs between cohorts yields estimates of cost
effectiveness.
We compared a cohort of 10 000 eligible women for
each strategy. The starting age of women in the model
is 42, as this is themean ageofwomen in all the ablation
randomised controlled trials, and the period covered is
a total of 10 years.6 7 10 We assume that all women will
becomemenopausal at the age of 52, the average age of
menopause in the UK. We considered these assump-
tions to reflect the evidence in the literature.6 These are
also the assumptions used by earlier authors.8 Each
model cycle lasts one month, representing the typical
menstrual cycle. The death rate from causes other than
procedures for heavymenstrual bleedingwas based on
values for women in the government actuary’s
Table 1 | Definition of health states for women after respective intervention pathways for treatment of heavy menstrual
bleeding
Endometrial ablation Hysterectomy Mirena
Menorrhagia All women in cohort have preoperative heavy menstrual bleeding
Hysterectomy If women have symptoms after first ablation, they
might choose to have hysterectomy. Hysterectomy
is also an option after failed repeat endometrial
ablation. This operation occurs 6 months after
decision. These women then follow the pathway
outlined in hysterectomy diagram (fig 3)
All women undergo hysterectomy —
Endometrial
ablation
techniques
Women undergo endometrial ablation by first or
second generation techniques
— —
Complica-
tions
After endometrial ablation, some women will
experience severe postoperative complications.
Perioperative complications are included in
endometrial ablation state
After hysterectomy, some women will
experience severe postoperative
complications. Effects of these might
last for 1 month. Operative
complications are included in
hysterectomy state
—
Well After endometrial ablation, complications, or
treatment failure, women are satisfied with
treatment
After convalescence women are
satisfied with treatment
After Mirena, women are satisfied with
treatment
Mirena — — All women have Mirena inserted
Symptomatic After endometrial ablation, complications,orbeing
well, heavy menstrual bleeding might recur
(treatment failure) at any time.Womenmightbe re-
treated (repeat ablation), become well, or have
hysterectomy after initial or repeat ablation
— After Mirena or being well, heavy
menstrual bleeding can recur (treatment
failure) at any time
Convales-
cence
— After hysterectomy both with and
without complications, period of
convalescence is experienced. This can
last up to 3 months
—
Repeat Repeat ablation (rollerball)—if heavy menstrual
bleeding recurs postoperatively, women might
choose to have second endometrial ablation,
which occurs 6 months after initial ablation. Only
one repeat endometrial ablation ispermittedand it
is always first generation technique (rollerball)
— Women can be re-treated, have second
generation endometrial ablation, or
remain symptomatic
Death Death from natural causes is possible. For hysterectomy and endometrial ablation, women
might also die as direct result of surgical procedure
—
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department life tables of England and Wales for the
years 1998-2008.11
Clinical assumptions and adverse events
The lifespan of Mirena is assumed to be five years.11 If
successful, treatment is repeated at five years. Treat-
ment failure with Mirena is assumed to be more evi-
dent in the first year.12 13 We also assumed a 2% rate of
insertion failure, where the procedure is repeated
within a month.13 If Mirena is unsuccessful, women
move to the second generation endometrial ablation
as indicated by the pathway. No adverse events asso-
ciated with Mirena were available in the literature.6 7
For first generation endometrial ablation techniques
and hysterectomywe used large national audits of both
as sources for perioperative and severe postoperative
adverse events (table 2). 14 5 Minor postoperative com-
plications were not modelled. For second generation
endometrial ablation techniques, we used complica-
tion rates of microwave endometrial ablation.15
Some of the data, specifically proportions in various
health states at points in time after initial treatment,
related to model outputs rather than model inputs.
We applied a method that can be called “probabilistic
calibration,” whereby model inputs for the relevant
parameters were sampled uniformly across the
plausible range and cost and QALY outcomes were
weighted according to the likelihood function compar-
ing the model proportions in the various health states
with the data.
A repeated intervention is assumed to indicate a fail-
ure in the initial procedure. The failure rate for endo-
metrial ablation is about 25-35%, inferred from the
number of repeat ablations and hysterectomies that
are carried out. This estimate does not include
women who return to their general practitioner for
medical treatment.7 We assumed that if endometrial
ablationof any type fails, repeat ablation (with first gen-
eration devices only) or hysterectomy would be
offered. In the model it is assumed that 60% of those
with recurrent heavy menstrual bleeding (sympto-
matic state) will have a repeat endometrial ablation
and 40% will have a hysterectomy.16 Only one repeat
ablation is offered.We further assumed that if the treat-
ment fails a second time, only hysterectomy is avail-
able. Complication rates for repeat ablations are
assumed to be double those incurred for the initial
ablation.17 We assumed that if symptoms do not recur
within two years of the initial ablation, then they are
unlikely to do so later, and therefore no repeat proce-
dure takes place thereafter. Thus we have limited the
time as towhen a repeat procedure, ablation, or hyster-
ectomy can occur to two years.
The transition probability for requiring a repeat pro-
cedure is time dependent and is reduced by a constant
factor each month. This reflects a decreasing hazard,
which is obvious from the individual patient data.7
We obtained information on perioperative and
severe postoperative adverse events with first genera-
tion endometrial ablation techniques from the MIS-
TLETOE study.14 For second generation techniques,
we used complication rates with microwave endo-
metrial ablation as a proxy15 because the complication
rates from MISTLETOE for the second generation
techniques refer to slightly outdated procedures and
are no longer relevant. In using the complication
rates with microwave endometrial ablation from the
study by Parkin et al15 (n=1400), we acknowledge that
the true incidence of complications might be underes-
timated. All data reported in this study were from a
Table 2 | Data used in model to determine cost effectiveness of different treatments for heavy
menstrual bleeding
Value and
source
Background mortality rate (from life tables) 0.00015
Proportion of women with symptoms (after initial ablation) who have repeat ablation* 0.416
Proportion of women with symptoms (after initial ablation) who have hysterectomy* 0.616
First generation techniques†
Operative complications 0.044514
Severe postoperative complications 0.029214
Death after operation 0.000214
Symptomatic after being well 0.0002206‡§
Symptomatic after operative complications or severe postoperative complications 0.01188§
Second generation techniques
Operative complications 0.002815
Severe postoperative complications 0.000715
Death after operation 015
Symptomatic after being well 0.0001864‡§
Symptomatic after operative complications or severe postoperative complications 0.05696‡§
Mirena
Proportion of women with coil in situ after 1 year 0.6806¶12
Proportion of women with coli in situ after 5 years 0.4790¶13
Insertion failure rate 0.016813
Hysterectomy**
Operative complications 0.03585
Severe postoperative complications 0.01025
Death after operation 0.00035
*Proportions reversed and varied extensively in sensitivity analysis with extreme values; model results were not
sensitive to this parameter.
†Complication and mortality rates in repeat ablation (rollerball) were double those in initial ablation.17
‡No of months remaining in model.
§Fit by calibration to individual patient data meta-analysis.
¶Figures are original values as reported in papers. Failure per month in year 1 and years 2-5 calculated.
**Complication and mortality rates adjusted for “dysfunctional uterine bleeding” population only.
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Fig 2 | Cost effectiveness acceptability frontier, showing
probability that preferred option is cost effective
(ICER=incremental cost effectiveness ratio)
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specialist centre and reported complication ratesmight
not be representative of other second generation
techniques.
Resource use and costs
All costs in the model are in UK £ (2008 value). We
used appropriate indices to inflate some of the costs
that were obtained from the literature.18 Table 3
shows the costs discounted at 3.5% a year (as perNICE
guidelines).8
The source for the costs of adverse events was NHS
2009 reference costs.19 We used the same cost for peri-
operative and severe postoperative complications for
each of the procedures included in the model. The
varying severity of complications of the two different
types of endometrial ablations and hysterectomy is
also reflected in costs.
Utility values
Published sources were used to identify the quality of
life weightings associated with each state in the
model.13 20 21 Table 4 describes these values in detail.
The quality of life data show that heavy menstrual
bleeding is associated with a quality of life value of
0.50, which means that women who have this condi-
tion have reported that they feel a loss in terms of qual-
ity of life value that is equivalent to half a year at full
health. If women have a successful first generation
ablation they move to the “well” state associated with
a quality of life value of 0.73.21 In contrast, after a suc-
cessful second generation ablation, women move to
the “well” state associated with a quality of life value
of 0.84. This is an assumption made in the absence of
available data, but relates to the same “well” state as
after successful experience with Mirena. This was
based on the fact that, if they are successful, second
generation techniques (generally speaking) perform
better, are less invasive, and have fewer adverse
events.7 If ablations of any type are unsuccessful and
a repeat ablation is required, however, they are always
first generation ablations and the associated quality of
life value is 0.73.
The quality of life value for convalescence after hys-
terectomy is estimated at 0.74.20 22 We assume that this
quality of life is not reached until one week after hys-
terectomy and assumed a zero quality of life value for
theweek immediately after the operation.This gives an
average quality of life over the month of 0.56. After a
successful hysterectomy, women move to the “well”
state associated with a quality of life value of 0.88.13
Table 3 | Costs associated with treatment for heavy menstrual bleeding in UK £ at 2008 prices
Description Unit cost Details Source
First generation ablation techniques* £1238 Costs in this study included pre-surgery treatment for endometrial ablations, technical equipment (varied
for each method), hospital costs, gynaecological outpatient costs, and re-treatment. Re-treatment
excluded from estimate because this is separate procedure included in model
Cameron, 199622
Second generation ablation techniques† £1101 Source for costs of MEA and TBEA report by Garside.9 Statistical weights for weighted cost mean obtained
from study reporting NHS hospital episode statistics of endometrial ablations from 1989-90 to 2005-5.
Garside, 20049
Repeat ablation (rollerball) £1238 Cost of repeat ablation was same as cost of first generation techniques described above. Additional cost
of GP consultation for referral from primary to secondary care included at £4618
Cameron, 199622
Hysterectomy £2162 For women who had hysterectomy after failed repeat ablation, additional cost of GP consultation for
referral from primary to secondary care included at £4618
Cameron, 199622
GP visit for referral to secondary care‡ £46 — PSSRU19
Mirena
Total initial stage cost £130.27 Procedure assumed to be performed in menstrual clinic as outpatient procedure. Total cost includes
those for device, initial consultation (10 minutes with nurse and 30minutes with specialist registrar). and
sterile pack for use during Mirena insertion
BNF, National
Collaborating Center
for Women’s and
Children’s Health
CG44, PSSRU
Discontinuation £28.34 Includes cost of consultation and consumables (sterile pack) used for removal of device
Adverse events§
First generation ablation techniques £2161 See text
National Schedule of
Reference Costs
Second generation ablation techniques £1198 See text
Hysterectomy £3008 See text
PSSRU= Personal Social Services Research Unit; BNF=British National Formulary.
*Weighted mean for transcervical resection of the endometrium and rollerball. Statistical weights assumed to be equal.
†Weighted mean for microwave endometrial ablation (MEA) and thermal balloon endometrial ablation (TBEA).
‡Cost of GP consultations included as part of referral to secondary care for second generation endometrial ablation (EA) after Mirena failed and for repeat ablation or hysterectomy after both
ablations failed.
§Values used for both “immediate operative adverse events” and “severe postoperative adverse events.”
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Fig 3 | Base case deterministic results of cost effectiveness of
different treatments for heavy menstrual bleeding (Mirena,
hysterectomy, and first and second generation ablation
techniques)
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For costs, we aggregated according to the distribu-
tions at the start of each cycle. This is necessary to
account for the full costs of initial treatment.
Analysis
All analyses are carried out from the perspective of the
UKNHS and are reported in terms of incremental cost
effectiveness ratios presented in terms of cost per qual-
ity adjusted life year (QALY).Dominance in the results
will exist if one strategy is found to be both cheaper and
more effective in terms of producing more QALYs.
We assessed uncertainty in the model parameters
through probabilistic sensitivity analysis. In its most
common form, this assigns to each input parameter a
specific distribution and, by drawing randomly from
those distributions, generates a large number of esti-
mates of mean cost and effectiveness. These estimates
are then used to form an empirical joint distribution of
the differences in cost and effectiveness between inter
ventions.23 24
We carried out one subgroup analysis and two alter-
native one way deterministic sensitivity analyses. The
subgroup analysis was carried out on the basis of the
length of the uterine cavity, on the rationale that abla-
tion (as opposed to hysterectomy) is more likely to be
successful in women with a shorter cavity.7
In the first deterministic sensitivity analysis we chan-
ged utilities from the base case, in which the mean uti-
lity values are used, to an analysis based on reported
median values from the study by Sculpher20 (table 4).
Use of the mean scores is most appropriate in eco-
nomic evaluation because if outliers are ignored it
could lead to the cost effectiveness analysis underesti-
mating costs or overestimating effects. Other pub-
lished studies used median values reported by
Sculpher,20 and notmeans, without explanation or jus-
tification. We believe this use to be inappropriate and
are unclear how the medians were estimated.9 In the
second deterministic sensitivity analysis we used the
“median” quality of life values from Sculpher20 and
set the quality of life value for the “well” state after
the intervention to the same value for both ablation
strategies and Mirena (0.90).
RESULTS
Table 5 presents a summary of the deterministic
results. The results show that the strategy that uses
first generation endometrial ablation as the first inter-
vention of the pathway is dominated by all the other
strategies as it is bothmore expensive and less effective
in termsof producingQALYs.The strategy that adopts
hysterectomy as the first and only intervention pro-
duces the most QALYs. In comparison with the strat-
egy that uses Mirena first, hysterectomy is more
expensive but generates moreQALYs. The incremen-
tal cost effectiveness ratio (ICER) representing the
value of the additional benefit of the hysterectomy
strategy compared with Mirena is £1440 (€1633,
$2350) per additional QALY. The hysterectomy strat-
egy also produces more QALYs than the second gen-
eration endometrial ablation strategy and the
estimated incremental cost effectiveness ratio for this
comparison is £970 per additional QALY.
Table 4 | Health state utilities used in model to determine cost effectiveness of different treatments for heavy menstrual bleeding
Utility
(SE or 95% CI) Median* Source Comment
Menorrhagia 0.50 (SE 0.04) 0.55 Sculpher, 199820 —
Dead 0 — — By definition
Hysterectomy 0.56 — — Assumed 25% less than “convalescence after hysterectomy”
Well after hysterectomy 0.88 (0.75 to 0.95)† — Hurskainen, 200413 —
Convalescence after hysterectomy 0.74 (SE 0.05) 0.95 Sculpher, 199820 —
Severe complications after hysterectomy 0.49 — Clegg, 200721 —
First generation ablation techniques 0.76 (SE 0.04) 0.85 Sculpher, 199820 Includes “convalescence after first generation techniques”
Well after first generation techniques 0.73 (SE 0.04) 0.90 Sculpher, 199820 —
Severe complications after first generation techniques 0.49 — — Same as complications after hysterectomy
Symptomatic after first generation techniques 0.50 (SE 0.04) 0.55 Sculpher, 199820 Same as “menorrhagia”
Second generation ablation techniques 0.76 (SE 0.04) — — Assumed same as first generation techniques
Well after second generation techniques 0.84 (0.73 to 0.93)† — — Same as Mirena
Severe complications after second generation techniques 0.49 — — Same as complications after hysterectomy
Symptomatic after second generation techniques 0.50 (SE 0.04) 0.55 Sculpher, 199820 Same as “menorrhagia”
Repeat ablation (rollerball) 0.76 (SE 0.04) — — Includes convalescence after first generation techniques
Well after repeat ablation 0.73 (SE 0.04) 0.90 Sculpher, 199820 —
Severe complications after repeat ablation 0.49 — — Same as complications after hysterectomy
Symptomatic after repeat ablation 0.50 (SE 0.04) 0.55 Sculpher, 199820 Same as “menorrhagia”
Mirena 0.84 (0.73 to 0.93)† — Hurskainen, 200413 Same as “well after Mirena” assumption
Well after Mirena 0.84 (0.73 to 0.93)† — Hurskainen, 200413 —
Symptomatic after Mirena 0.50 (SE 0.04) — Sculpher, 199820 Same as “menorrhagia”
*Median values used in two one-way sensitivity analyses.
†Mean and width of confidence intervals fitted.
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The Mirena strategy dominates the first generation
endometrial ablation strategy, being cheaper andmore
effective in producing QALYs. But though it is also
cheaper than second generation endometrial ablation,
in this comparison it produces fewer QALYs. The
incremental cost effectiveness ratio for the second gen-
eration endometrial ablation versus Mirena is £2980
per additional QALY.
Figure 2 shows the result of the probabilistic sensitiv-
ity analysis. Detailed interpretation of this analysis and
additional value of information analysis is presented
elsewhere.6 Briefly, it shows the probability that the
preferred option is cost effective for any given thresh-
old incremental cost effectiveness ratio for all but a few
replications—and the few account for a negligible
probability. Mirena was the least costly option and,
for low acceptable threshold incremental cost effec-
tiveness ratios, Mirena is preferred with certainty
within this model given its assumptions. But as the
threshold incremental cost effectiveness ratio increases
hysterectomy becomes the preferred option.
In some replications of the model (accounting for
20% of the probability), hysterectomy was not the
most effective option (in terms of total number of
QALYs). At an incremental cost effectiveness ratio of
£1440, the preferred option changes from Mirena to
hysterectomy, so there is a discontinuity in the cost
effectiveness acceptability curve.
In the subgroup analysis, carried out to explore the
impact of the length of the uterine cavity on cost effec-
tiveness of the alternative interventions for heavymen-
strual bleeding, we carried out two separate analyses
and a corresponding probabilistic sensitivity analysis.
The results of the subgroup analysis showed a small
effect of shorter and longer uterine cavity length,
which was in the same direction for both. For both
cases the results moved slightly so that first generation
ablation was no longer “dominated” by hysterectomy
and the incremental cost per additional QALY of hys-
terectomy compared with other strategies was slightly
higher (less favourable) than in the base case. There is,
however, unlikely to be a change in the decision based
on these results and hysterectomy remains the pre-
ferred strategy. The results of the probabilistic sensitiv-
ity analysis reinforced the results of this deterministic
subgroup analysis and are not presented.
In a further deterministic sensitivity analysis, we
changed the utilities from the base case in which the
mean utility values are used, to reported median
values. In the first deterministic sensitivity analysis
we used the “median” quality of life values from
Sculpher20 and assumed the quality of life scores as a
result of first and second generation ablation were
equal based onmedian values (well after first or second
generation endometrial ablation 0.90). The key change
in results compared with the base case is that there is a
clear shift away from the hysterectomy strategy in
favour of second generation endometrial ablation.
This dominates first generation endometrial ablation
as before, but now also dominates hysterectomy.
Meanwhile, in this sensitivity analysis the incremental
cost effectiveness ratio for second generation endo-
metrial ablation versus the Mirena strategy was
£1000 per additional QALY.
The results of the second deterministic sensitivity
analysis are similar to those presented in the first.
Once again the strategy of second generation endo-
metrial ablation dominates first generation endo-
metrial ablation and hysterectomy, in contrast with
the base case. The incremental cost effectiveness ratio
for second generation endometrial ablation versus
Mirena is £3624 per additional QALY.
Figures 3 and 4 summarise and compare the key
findings from changing the utility values (presented
in the first and second sensitivity analyses) with the
base case. Figure 3 shows that with baseline (mean)
utilities, Mirena is the least costly strategy and hyster-
ectomy the most effective. The strategy that starts with
first generation endometrial ablation is simply domi-
nated by all of the other strategies. The strategy that
starts with second generation endometrial ablation is
excluded by extended dominance between Mirena
and hysterectomy.
Figure 4 shows the same costs for all strategies as
figure 3 but the total QALYs are increased. By using
the median utility values, second generation ablation
now becomes the most effective strategy: both first
Table 5 | Summary of deterministic base case, subgroup, and sensitivity analyses of model to
determine cost effectiveness of different treatments for heavy menstrual bleeding
Total costs per
strategy (£1000)
Total QALYs
per strategy
Incremental cost
effectiveness
ratio (ICER)
(v hysterectomy)
Summary of base case deterministic results
First generation endometrial ablation 23 590 63 745 Dominated
Second generation endometrial ablation 19 470 69 678 970
Mirena 16 150 68 566 1440
Hysterectomy 23 000 73 332 —
Summary of subgroup analysis based on short uterine cavity length
First generation endometrial ablation 21 356 63 143 161
Second generation endometrial ablation 19 264 69 582 996
Mirena 15 667 68 201 1429
Hysterectomy 23 000 73 332 —
Summary of subgroup analysis based on long uterine cavity length
First generation endometrial ablation 20 104 62 809 275
Second generation endometrial ablation 17 986 69 655 1364
Mirena 15 158 68 558 1642
Hysterectomy 23 000 73 332 —
Deterministic sensitivity analysis 1: where mean values are substituted by median values*
First generation endometrial ablation 23 588 74 218 2225
Second generation endometrial ablation 19 466 74 402 Dominates
Mirena 16 151 71 089 2391
Hysterectomy 23 000 73 954 —
Deterministic sensitivity analysis 2: where mean values are substituted by median values†
First generation endometrial ablation 23 588 74 218 2225
Second generation endometrial ablation 19 466 74 402 Dominates
Mirena 16 151 73 488 14 683
Hysterectomy 23 000 73 954 —
*Assumes that well after intervention for first and second generation ablation are equal but not for Mirena.
†Assumes that well post intervention is same for both ablation strategies and Mirena.
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generation endometrial ablation and hysterectomy are
simply dominated by second generation endometrial
ablation.
DISCUSSION
Statement of principal findings
The results of the base case analysis show that hyster-
ectomy is the preferred strategy as the first intervention
for heavy menstrual bleeding. Hysterectomy domi-
nates the strategy that uses first generation endometrial
ablation as the initial intervention. Although hysterect-
omy ismore expensive, it producesmoreQALYs rela-
tive to other remaining strategies and is likely to be
considered cost effective: the incremental cost effec-
tiveness ratio for hysterectomy compared withMirena
is £1440 per additional QALY. These results suggest
that hysterectomy first would be considered the pre-
ferred strategy in light of the acceptable thresholds
used byNICE,which tends to accept new technologies
if the incremental cost effectiveness ratio is within
£20 000 per additional QALY.
Our main results suggesting the relative cost effec-
tiveness of hysterectomywere robust to all the sensitiv-
ity and subgroup analyses, with the exception of the
sensitivity analysis carried out on the utility data. This
was based on an analysis that used the reported values
of utilities that are available in the published literature,
specifically the “mean”’ reported utility values, which
is appropriate.25 26
Strengths and limitations
Themajor strength of the economic component of this
study is that it is based on a sophisticated Markov
model, whichwas informed by data from an individual
patient level datameta-analysis of randomised trials. A
multidisciplinary team including economists, expert
clinicians, and statisticians provided input into the
model structure primarily based on the evidence in
the literature. All assumptions used in the model
were based on the available evidence as far as possible.
All required assumptions were agreed with the team
before the analysis was carried out and without knowl-
edge of how these assumptionsmight affect the results.
In terms of limitations, it is possible that we did not
include all aspects of costs and outcome as the utilities
used are likely to reflect the satisfaction of the out-
comes only. Once women have had a hysterectomy,
for example, their satisfaction is high because, in con-
trast with the other interventions, they experience no
bleeding at all. But the utilitymeasure does not capture
the anxiety before hysterectomy associatedwithmajor
surgery and general anaesthetic. Such anxieties can
lead to decisions that avoid major surgery as a first
step and to try other less invasive options for as long
as possible. The perspective of the analysis does not
include the costs to women associated with six to
eight weeks’ convalescence after hysterectomy.
Furthermore, the model’s time horizon and the lack
of long term data exclude possible effects of long
term complications such as urinary stress incontinence
for which surgery is required.27
Strengths, weaknesses, and assumptions in relation to
other studies
With regard to the utility values that have been used in
the current study the followingpoints areworth noting.
First, the paper by Sculpher20 has been extensively
referenced in the literature. Other studies, including
that by Garside et al,9 have used the median values
from that paper and not the means, seemingly without
justification or a critique of the face validity of these
data. Furthermore, for economic evaluation it is the
mean values that are most appropriate to use as it is
considered important to capture outliers to avoid
underestimating costs or overestimating benefits.25 26
Our results suggest that hysterectomy is the most
cost effective strategy, but we must emphasise the
uncertainty in the utility data. Mirena has not been
extensively evaluated, and there are only limited data
available on long term follow-up.7
Comparison with other studies
The results of the model based economic evaluation
reported by Garside et al also showed hysterectomy
was the most cost effective strategy for treating heavy
menstrual bleeding.9 They compared second genera-
tion with first generation ablative techniques and hys-
terectomy. Mirena was not included in their
comparative analysis.When compared with hysterect-
omy, second generation ablative techniques were
found to be less costly but also provided fewer
QALYs. The authors used median, not mean, utility
values in their analysis but without justification. They
reported that the results of their model were highly
sensitive to the utility values associated with being
well after ablation and recommended that results are
interpreted with caution because of this sensitivity.9 In
our sensitivity analysis, whenweused the samemedian
value for the utilities, as opposed to the means, the
results showed that second generation endometrial
ablation was the most cost effective strategy.
Our results do not concur with the result of the Fin-
nish trial byHurskainen et al, which comparedMirena
with hysterectomy and found Mirena to be cost
Total QALYs (000s)
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Fig 4 | Deterministic sensitivity analysis with median utility
values instead of means for cost effectiveness of different
treatments for heavy menstrual bleeding (Mirena,
hysterectomy, and first and second generation ablation
techniques)
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effective at five years.13 There was no significant differ-
ence in quality of life scores at five years, as measured
by the EQ-5D instrument, between the two treatment
groups. But this is unsurprising as 40%ofwomen in the
Mirena arm went on to have a hysterectomy and com-
pleted EQ-5D at the end of treatment.13 It is also a
cause for concern that mean direct costs in the Mirena
arm remained significantly lower ($1892) than the hys-
terectomy arm ($2787), despite the substantial number
subsequently undergoing hysterectomy.
An economicmodelling study undertaken to inform
NICE guidelines8 suggested that Mirena is cost effec-
tive when comparedwith both hormonal and non-hor-
monal treatment. Mirena generated more QALYs at a
lower cost than any othermedical or surgical treatment
strategy considered. Our model differed from the
NICE model in terms of the assumptions. The NICE
model assumed that within the five year lifespan of
Mirena, some women who experienced failure with
Mirena would move straight to hysterectomy (based
on data from Hurskainen et al13). In contrast, in our
study, our assumption (based on advice from clinical
colleagues) was that all women who experienced fail-
ure with the Mirena strategy would, in the first
instance, follow the second generation endometrial
ablation pathway. This helps to explain the difference
in results and the relative preference in our analysis for
hysterectomy over Mirena. Furthermore, it also high-
lights the importance of hysterectomy, as integral to
NICE guidance supportingMirena in the first instance
is the belief that hysterectomy is available if Mirena
fails.
An implicit assumption in this and other similar stu-
dies is that there exists equivalent ability to undertake
all these procedures both froma time and skill base, but
this is unlikely to be true. For example, Mirena can be
fitted in primary care; second generation ablative tech-
niques, while requiring use of a hospital, can be carried
out by specialist after minimal training in an outpatient
setting; but hysterectomy can be undertaken only by
more highly trained specialists in inpatient theatre
suites. While these differences are reflected in the
costs of the procedures used in the analyses, constraints
in available capacity and skills are not.
Implications
Our results suggest that, based on current best avail-
able data, which are limited, Mirena is not a robust
cost effective strategy compared with hysterectomy.
These results contradict current opinion and practice
in gynaecology, which has seen a reduction in the rate
of hysterectomy for heavymenstrual bleeding over the
past decade or so. Our evaluation is based on the best
available data and the assumptions used in the model
were made before the analysis and are unbiased. The
data, however, might not reflect the decision making
process between women and doctors for whom mini-
mal risks and relatively quick and convenient treat-
ments might offset the higher failure rates associated
with Mirena initially, knowing that a more definitive
treatment is still available. This leads to a potential con-
flict between an individual approach based on choice
and a utilitarian one based on maximising gains for
society.
Unanswered questions for future research
We used a sophisticated model, data from an indivi-
dual patient data meta-analysis, and all available data
on quality of life associated with the available inter-
ventions for the outcomes for alternative treatments
for heavy menstrual bleeding.
One of the main causes of uncertainty is with regard
to the utility values associated with alternative inter-
ventions and their success. There would be little
value in future studies comparing the outcomes and
costs of any alternative interventions to treat women
for heavy menstrual bleeding without undertaking a
comprehensive study to clarify the quality of life asso-
ciated with the outcomes of the alternative inter-
ventions.
Our results show that more robust clinical data
would enhance clinical decision making, in particular
with regard to interventions such as Mirena, for which
there are limited follow-up data. Some of the current
authors are involved in the Birmingham based
ECLIPSE trial, which is a large UK funded
(NCCHTA) trial that will provide evidence on
whether Mirena is preferable to standard oral treat-
ments for heavy menstrual bleeding. Several
approaches to assessing quality of life issues and pre-
ferences are currently being considered.
Preferences of women and clinicians will continue to
be extremely influential in decision making. Many
clinicians believe that a “one size fits all” approach to
the treatment of heavy menstrual bleeding is impossi-
ble. As individual choices can determine perceived
success, eliciting preferences is also extremely relevant
in this context.28
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Less invasive alternatives to hysterectomy for the treatment of heavy menstrual bleeding,
such as endometrial ablation and Mirena, have become increasing popular
As second generation endometrial ablation techniques and Mirena are cheaper and less
invasive, they are likely to be preferred to hysterectomy
WHAT THIS STUDY ADDS
Second generation non-hysteroscopic endometrial ablation and Mirena are both less costly
and produce more QALYS than first generation techniques
Based on current best available evidence Mirena is not a cost effective strategy compared
with hysterectomy
Based on all available evidence on effectiveness, cost, and utility values, hysterectomy
produces cost effectiveness ratios that are likely to be accepted by decision makers
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